Lentitek and Annogen join forces to improve the quality and safety of T-cell therapies

Barcelona, The Netherlands – September 10, 2025

Lentitek and Annogen join forces to improve the quality and safety of T-cell therapies. This collaboration, jointly announced at the CGTI Leadership Summit today, aims to improve lentivirus-based CAR-T therapies by eliminating undesired transgene expression during viral vector manufacturing as well as restricting in vivo expression of the CAR to T-cells.

Annogen has developed a range of novel, validated promoters designed to drive high expression specifically in conventional T-cells but not in >20 other cell types, including the HEK293T cells used to manufacture lentiviral vectors, e.g. for T-cell therapies. This precision is crucial as expression of the transgene both during vector production and in non-target cells in vivo can compromise efficacy and biosafety.

Lentitek has a unique vector manufacturing technology preventing incorrect splicing and associated unwanted payload expression, which will now be combined with Annogen’s T-cell specific promoters. We believe that the combinations of our technologies has the potential to raise the bar for the next generation of in vivo CAR-T therapies, ensuring safer, more effective treatments for patients.

——

Edinburgh-based Lentitek Ltd has a unique manufacturing technology that can significantly enhance lentiviral vector quality, purity and yield by minimizing vector genome splicing and payload breakthrough expression.

Amsterdam-based Annogen BV is the go-to partner for advanced therapy developers, providing off-the-shelf promoters and tailored promoter designs, validated through large-scale in vitro and in vivo screening.